Compare Lumen Technologies Inc (LUMN) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lumen Technologies Inc trades at $4.52 (market cap $4.69B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Lumen Technologies Inc is far larger — about 4.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LUMN | MRVI | |
|---|---|---|
Market Cap | $4.69B | $977.37M |
Volume | 25,477,875 | 2,742,564 |
Sector | Media | Health |
52-Week High | $11.83 | $9.00 |
52-Week Low | $4.55 | $2.83 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $16.31B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $4.99, down 1.19% on the day, with a bearish technical outlook and mixed earnings history. Revenue has declined from $17.5B in 2022 to $12.4B in 2025, with a net loss of $1.74B last year. The company is pivoting to AI and digital networking services, recently announcing a Nasdaq listing and launching Intelligent Internet to capture enterprise demand.
The stock presents a high-risk turnaround opportunity, with deep value indicated by a low P/S of 0.42 but significant challenges including high debt, negative margins, and analyst skepticism. Strategic growth in AI services offers potential upside, but legacy declines and financial instability pose substantial risks for investors.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
